LTF : Bullish and Bearish Analyst Opinions

Spevak explicitly states that the rise of GLP-1 drugs has been the "complete opposite" of a death knell for gyms. He notes that users are realizing they need "lifestyle change" and resistance training to avoid side effects (muscle loss). The market initially feared GLP-1s would make gyms obsolete. Spevak's data suggests a symbiotic relationship: as LLY/NVO sell more drugs, the "prescription" increasingly includes strength training. This benefits gym operators (LTF is the closest public proxy to Equinox's luxury tier; PLNT captures the mass market). Long the drug makers (LLY, NVO) and the gym operators (LTF, PLNT) as a combined "health span" trade. High valuation of GLP-1 stocks; potential for gym churn if economic conditions worsen for the aspirational class.